Abstract: The present invention provides a recombinant chicken interleukin-1? protein for producing antibody early and retaining for a longer period of time, which has a sequence of SEQ ID NO:2 or SEQ ID NO:3. The recombinant chicken interleukin-1? protein is created by using point mutation in a genetic engineering method; it can significantly improve the original vaccine efficacy to enhance antibody responses, produce antibody one week earlier and extend the protective effect until chickens sold off. Therefore, the recombinant chicken interleukin-1? protein of the present invention can produce significant higher antibody responses than the with-type chicken interleukin-1? protein, it helps to develop avian interleukin-1? vaccine adjuvant and uses in medical application and livestock production.

Abstract: The present invention provides a mutant chicken interleukin-1? protein as a chicken interleukin-1? antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1? peptides. The mutant chicken interleukin-1? protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1? protein of the present invention can be used as antiviral and anti-inflammatory medication.

Abstract: The present invention provides a mutant chicken interleukin-1? protein as a chicken interleukin-1? antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1? peptides. The mutant chicken interleukin-1? protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1? protein of the present invention can be used as antiviral and anti-inflammatory medication.

Abstract: The present invention provides a recombinant chicken interleukin-1? protein for producing antibody early and retaining for a longer period of time, which has a sequence of SEQ ID NO:2 or SEQ ID NO:3. The recombinant chicken interleukin-1? protein is created by using point mutation in a genetic engineering method; it can significantly improve the original vaccine efficacy to enhance antibody responses, produce antibody one week earlier and extend the protective effect until chickens sold off. Therefore, the recombinant chicken interleukin-1? protein of the present invention can produce significant higher antibody responses than the with-type chicken interleukin-1? protein, it helps to develop avian interleikin-1? vaccine adjuvant and uses in medical application and livestock production.

Abstract: The present invention provides a polypeptide adjuvant composition with thermostability, which is designed from wild-type chicken interleikin-1? to construct a new chicken interleikin-1?, named CP-interleikin-1?. The CP-interleikin-1? having improved heat resistance keeps the original biological activity, and which helps to develop protein adjuvant with high efficiency and uses in medical application. The present invention also provides a method of manufacturing such polypeptide adjuvant composition.

Abstract: The present invention provides a polypeptide adjuvant composition with thermostability, which is designed from wild-type chicken interleikin-1? to construct a new chicken interleikin-1?, named CP-interleikin-1?. The CP-interleikin-1? having improved heat resistance keeps the original biological activity, and which helps to develop protein adjuvant with high efficiency and uses in medical application. The present invention also provides a method of manufacturing such polypeptide adjuvant composition.